[Federal Register Volume 81, Number 3 (Wednesday, January 6, 2016)]
[Notices]
[Page 513]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-33266]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--National Chemical & Biological Defense 
Consortium

    Notice is hereby given that, on November 13, 2015, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), National Chemical & 
Biological Defense Consortium (``NCBDC'') has filed written 
notifications simultaneously with the Attorney General and the Federal 
Trade Commission disclosing (1) the identities of the parties to the 
venture and (2) the nature and objectives of the venture. The 
notifications were filed for the purpose of invoking the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances.
    Pursuant to section 6(b) of the Act, the identities of the parties 
to the venture are: AbViro LLC, Bethesda, MD; Advanced Nuclear Devices 
Corporation, Hilton Head Island, SC; Aequor, Inc., Oceanside, CA; 
Aeterna Zentaris, Qu[eacute]bec, CANADA; AIBiotech, Richmond, VA; 
Allied Technologies & Consulting, LLC, Frederick, MD; AMH Consulting, 
Potomac, MD; AntibioTx ApS, H[oslash]rsholm, DENMARK; Approach 
Robotics, Ridgecrest, CA; Aradigm Corporation, Hayward, CA; Artificial 
Cell Technologies, Inc., New Haven, CT; BalinBac Therapeutics, Inc., 
Princeton, NJ; Battelle Memorial Institute, Columbus, OH; BioFactura, 
Inc., Frederick, MD; BioStat Solutions, Inc., Frederick, MD; Burrell 
International Group, LLC, Frederick, MD; CACI, Arlington, VA; CFD 
Research Corporation, Huntsville, AL; CONTINUUS Pharmaceuticals, Inc., 
Woburn, MA; Creare LLC, Hanover, NH; CSC Government Solutions LLC, 
Falls Church, VA; CUBRC, Inc., Buffalo, NY; DALI Medical Devices Ltd., 
Yavne, ISRAEL; Design West Technologies Inc., Tustin, CA; Draper 
Laboratory, Cambridge, MA; Eagle Applied Science, San Antonio, TX; 
Emergent, Inc., North Charleston, SC; Equivital Inc., New York, NY; EZ-
A Consulting, LLC, Bel Air, MD; First Line Technology, Chantilly, VA; 
General Dynamics Information Technology, San Diego, CA; GeoVax Labs, 
Inc., Smyrna, GA; Ginkgo BioWorks, Boston, MA; Goldbelt Raven, LLC, 
Herndon, VA; Hackensack University Medical Center, Hackensack, NJ; 
iBio, Inc., New York, NY; IIT Research Institute, Chicago, IL; Immune 
Biosolutions, Inc., Qu[eacute]bec, CANADA; Inficon, East Syracuse, NY; 
Integrated BioTherapeutics, Inc., Gaithersburg, MD; InvivoSciences 
Inc., Madison, WI; Jade Therapeutics, Inc., Salt Lake City, UT; JRAD, 
Stafford, VA; KD Analytical, Harrisburg, PA; Kestrel Corporation, 
Albuquerque, NM; Kinnear Pharmaceuticals, LLC, Columbus, OH; Kiyatec, 
Greenville, SC; L-3 Communications, New York, NY; Latham BioPharm 
Group, Inc., Maynard, MA; Luminex Corporation, Austin, TX; MainStream 
Global Solutions, Robins, IA; Mapp Biopharmaceutical, Inc., San Diego, 
CA; MaxCyte, Inc., Gaithersburg, MD; Med-Ally, Canton, CT; MedPro 
Technologies, LLC, San Antonio, TX; Mesa Science Associates Inc., 
Frederick, MD; Michael T. Brown Consulting, LLC, Austin, TX; Microbial 
Robotics, LLC, Covington, KY; Mike Sellers & Associates, Beavercreek, 
OH; MLT Systems, Stafford, VA; MRI Global, Kansas City, MO; 
Nanotherapeutics, Inc., Alachua, FL; New York Blood Center Inc., New 
York, NY; Novici Biotech LLC, Vacaville, CA; Novozymes, Inc., 
Franklinton, NC; OrPro Therapeutics, Inc., San Diego, CA; Parsons, 
Washington, DC; Pertexa, Ridgecrest, CA; Philips, Foster City, CA; PrEP 
Biopharm, Rumson, NJ; Purdue University, West Lafayette, IN; 
QuickSilver Analytics, Belcamp, MD; Quintiles, Durham, NC; Rapid 
Pathogen Screening, Inc. (RPS), Sarasota, FL; Recursion 
Pharmaceuticals, Salt Lake City, UT; RTI International, Coraopolis, PA; 
San Diego State University, San Diego, CA; Science Applications 
International Corporation, McLean, VA; SciTech Services Inc., Havre De 
Grace, MD; Shield Analysis Technology, LLC, Manassas, VA; SIGA 
Technologies, Inc., New York, NY; Signature Science, Austin, TX; Smart 
Consulting Group, LLC, West Chester, PA; Southern Research Institute, 
Birmingham, AL; Southwest Research Institute, San Antonio, TX; Spero 
Therapeutics, Cambridge, MA; SRI International, Princeton, NJ; 
Strategic Solutions Integrated, Arlington, VA; TDA Research, Inc., 
Wheat Ridge, CO; Tetracore, Inc., Rockville, MD; Texas A&M, Bryan, TX; 
TheraSource LLC, Roslyn, NY; Trideum, Huntsville, AL; TriLink 
BioTechnologies, San Diego, CA; Ubiquitome Limited, Auckland, NEW 
ZEALAND; University of Florida Institute for Therapeutic Innovation, 
Gainesville, FL; University of Nebraska Medical Center--Department of 
Pathology and Microbiology, Omaha, NE; University of North Texas Health 
Sciences Center, Fort Worth, TX; University of Pittsburgh--Center for 
Military Medicine Research, Pittsburgh, PA; and Vaxess Technologies, 
Inc., Cambridge, MA. The general area of NCBDC's planned activity is 
advanced development efforts to support the Department of Defense's 
medical pharmaceutical and diagnostic requirements as related to 
enhancing the mission effectiveness of military personnel through (i) 
detection--systems and devices to identify CBRN (Chemical Biological 
Radiological and Nuclear) agents and assist in making medical 
decisions; (ii) prevention--prophylaxis, pretreatment, and post-
exposure prophylaxis; (iii) treatment--therapeutics (post-exposure, 
post-symptomatic); and (iv) chemical--medical protection against use of 
chemical agents.

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2015-33266 Filed 1-5-16; 8:45 am]
 BILLING CODE P